Trust Co. of Virginia VA Has $938,000 Position in Pfizer Inc. (NYSE:PFE)

Trust Co. of Virginia VA lessened its stake in shares of Pfizer Inc. (NYSE:PFE) by 10.3% during the first quarter, Holdings Channel.com reports. The fund owned 33,788 shares of the biopharmaceutical company’s stock after selling 3,862 shares during the period. Trust Co. of Virginia VA’s holdings in Pfizer were worth $938,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently added to or reduced their stakes in PFE. GoalVest Advisory LLC increased its stake in Pfizer by 304.9% during the 4th quarter. GoalVest Advisory LLC now owns 1,077 shares of the biopharmaceutical company’s stock worth $31,000 after acquiring an additional 811 shares during the period. Creekmur Asset Management LLC bought a new position in shares of Pfizer in the 4th quarter valued at $32,000. VisionPoint Advisory Group LLC increased its stake in shares of Pfizer by 52,350.0% in the 3rd quarter. VisionPoint Advisory Group LLC now owns 1,049 shares of the biopharmaceutical company’s stock valued at $35,000 after purchasing an additional 1,047 shares during the last quarter. Tennessee Valley Asset Management Partners bought a new position in shares of Pfizer in the 4th quarter valued at $36,000. Finally, DiNuzzo Private Wealth Inc. bought a new position in shares of Pfizer in the 4th quarter valued at $37,000. Institutional investors own 68.36% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on the company. BMO Capital Markets reiterated an “outperform” rating and issued a $36.00 price target (up previously from $33.00) on shares of Pfizer in a research note on Thursday, May 2nd. Argus lowered Pfizer from a “buy” rating to a “hold” rating in a research note on Friday, March 22nd. Cantor Fitzgerald reiterated an “overweight” rating and issued a $45.00 price target on shares of Pfizer in a research note on Wednesday. Finally, Morgan Stanley raised their price objective on Pfizer from $28.00 to $29.00 and gave the company an “equal weight” rating in a report on Thursday, May 2nd. Ten research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $35.86.

Pfizer Trading Up 0.6 %

PFE traded up $0.18 during midday trading on Friday, hitting $27.98. 33,189,215 shares of the company were exchanged, compared to its average volume of 34,031,364. The firm has a market capitalization of $158.55 billion, a P/E ratio of -466.42, a P/E/G ratio of 1.09 and a beta of 0.70. Pfizer Inc. has a 1-year low of $25.20 and a 1-year high of $37.80. The firm’s 50 day moving average price is $27.90 and its 200-day moving average price is $27.69. The company has a quick ratio of 0.78, a current ratio of 1.05 and a debt-to-equity ratio of 0.66.

Pfizer (NYSE:PFE) last announced its earnings results on Wednesday, May 1st. The biopharmaceutical company reported $0.82 EPS for the quarter, topping the consensus estimate of $0.56 by $0.26. The firm had revenue of $14.88 billion for the quarter, compared to the consensus estimate of $13.87 billion. Pfizer had a positive return on equity of 8.64% and a negative net margin of 0.56%. The business’s quarterly revenue was down 19.5% compared to the same quarter last year. During the same period in the previous year, the business earned $1.23 EPS. As a group, equities analysts forecast that Pfizer Inc. will post 2.38 EPS for the current fiscal year.

Pfizer Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 3rd. Stockholders of record on Friday, July 26th will be paid a $0.42 dividend. This represents a $1.68 dividend on an annualized basis and a dividend yield of 6.00%. The ex-dividend date of this dividend is Thursday, July 25th. Pfizer’s dividend payout ratio is -2,799.53%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.